VanEck Biotech ETF (NASDAQ:BBH) Short Interest Update

VanEck Biotech ETF (NASDAQ:BBH) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totaling 7,633 shares, a growth of 50.7% from the March 15th total of 5,065 shares. Currently, 0.4% of the company’s shares are sold short. Based on an average trading volume of 6,538 shares, the short-interest ratio is currently 1.2 days.

VanEck Biotech ETF Trading Up 2.0%

Shares of NASDAQ:BBH opened at $190.27 on Tuesday. The firm’s 50 day simple moving average is $190.93 and its 200 day simple moving average is $188.35. VanEck Biotech ETF has a fifty-two week low of $139.92 and a fifty-two week high of $202.91.

Institutional Trading of VanEck Biotech ETF

A number of large investors have recently bought and sold shares of the business. Corient Private Wealth LLC increased its stake in VanEck Biotech ETF by 9.6% during the 4th quarter. Corient Private Wealth LLC now owns 5,483 shares of the company’s stock worth $1,041,000 after purchasing an additional 478 shares in the last quarter. Empowered Funds LLC bought a new stake in VanEck Biotech ETF during the 4th quarter worth approximately $38,000. MML Investors Services LLC bought a new stake in VanEck Biotech ETF during the 4th quarter worth approximately $384,000. Evelyn Partners Asset Management Ltd increased its stake in VanEck Biotech ETF by 16.9% during the 4th quarter. Evelyn Partners Asset Management Ltd now owns 941 shares of the company’s stock worth $178,000 after purchasing an additional 136 shares in the last quarter. Finally, Atlas Capital Advisors Inc. bought a new stake in VanEck Biotech ETF during the 4th quarter worth approximately $1,079,000. 32.05% of the stock is owned by institutional investors.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.